Thoratec Hopes MCAC Will Follow Blues’ Lead To Cover Destination LVADs
This article was originally published in The Gray Sheet
Executive Summary
Thoratec expects to meet with the Medicare Coverage Advisory Committee in early March to discuss expanding coverage of the HeartMate SNAP-VE left-ventricular assist device to include destination therapy for end-stage heart failure patients
You may also be interested in...
Thoratec HeartMate Gradual Roll-Out, Center Criteria Counseled By MCAC
Thoratec expects the Centers for Medicare & Medicaid Services to announce plans for national coverage of the HeartMate VE left ventricular assist device as a destination therapy by June
Thoratec HeartMate Gradual Roll-Out, Center Criteria Counseled By MCAC
Thoratec expects the Centers for Medicare & Medicaid Services to announce plans for national coverage of the HeartMate VE left ventricular assist device as a destination therapy by June
FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis